FDA Safety Changes: Levitra, Minocin, Zyvox
This activity is part of an ongoing CME/CE initiative to provide information on labeling changes reported by the FDA. Activities of this nature will be posted on Medscape on a weekly basis.
August 8, 2007 — The US Food and Drug Administration (FDA) has approved safety labeling revisions to advise of drug interactions with vardenafil and the additive effect on QT interval prolongation associated with concomitant use of certain medications, and the potential for development of Clostridium difficile-associated diarrhea more than 2 months after completion of therapy with minocycline HCl or linezolid. [Read more →]